At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PBE INVESCO BIOTECHNOLOGY & GENOME ETF
Market Closed 08-28 16:00:00 EDT
96.32
-2.22
-2.25%
盘后96.32
+0.000.00%
19:30 EDT
High97.12Low96.32Vol7.04K
Open96.94D1 Closing98.54Amplitude0.81%
Mkt Cap396.84MTradable Cap396.84MTotal Shares4.12M
T/O680.94KT/O Rate0.17%Tradable Shares4.12M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Crinetics Shareholders Approve Vertex Acquisition at Special Meeting
TIPRANKS  ·  08-29 05:33
Crinetics Shareholders Approve Vertex Acquisition at Special Meeting
Biogen Inc. Stock Underperforms Friday When Compared to Competitors
Dow Jones  ·  08-29 04:57
Biogen Inc. Stock Underperforms Friday When Compared to Competitors
Amgen Inc. Stock Underperforms Friday When Compared to Competitors
Dow Jones  ·  08-29 04:34
Amgen Inc. Stock Underperforms Friday When Compared to Competitors
Vertex Tests VX-407’s Impact on Birth Control: What It Means for VRTX Investors
TIPRANKS  ·  08-29 00:30
Vertex Tests VX-407’s Impact on Birth Control: What It Means for VRTX Investors
Amgen’s Pediatric Psoriasis Study Wrap-Up: What Apremilast Safety Data Means for Investors
TIPRANKS  ·  08-29 00:30
Amgen’s Pediatric Psoriasis Study Wrap-Up: What Apremilast Safety Data Means for Investors
Alnylam, Ionis Fall as Heart-Drug Data Raise Doubts over Combination Treatment
Reuters  ·  08-28 20:43
Alnylam, Ionis Fall as Heart-Drug Data Raise Doubts over Combination Treatment
Political and General News Events from August 28
Reuters  ·  08-28 20:30
Political and General News Events from August 28
Biogen CEO Viehbacher to Speak at Morgan Stanley Global Healthcare Conference
Reuters  ·  08-28 04:10
Biogen CEO Viehbacher to Speak at Morgan Stanley Global Healthcare Conference
Amgen’s AMG 691 Phase 1 Trial Targets Key Growth in Asian Markets
TIPRANKS  ·  08-28 00:31
Amgen’s AMG 691 Phase 1 Trial Targets Key Growth in Asian Markets
Analysts Offer Insights on Healthcare Companies: Verrica Pharmaceuticals (VRCA) and Amgen (AMGN)
TIPRANKS  ·  08-27 23:20
Analysts Offer Insights on Healthcare Companies: Verrica Pharmaceuticals (VRCA) and Amgen (AMGN)
HBM Holdings FY26 H1 Profit Falls 11.16% to US$ 64.85 Million; Revenue Rises 20.9% to US$ 122.49 Million
Reuters  ·  08-27 22:01
HBM Holdings FY26 H1 Profit Falls 11.16% to US$ 64.85 Million; Revenue Rises 20.9% to US$ 122.49 Million
Amgen, AstraZeneca announce Crossing trial showed ‘meaningful’ improvements
TIPRANKS  ·  08-27 19:15
Amgen, AstraZeneca announce Crossing trial showed ‘meaningful’ improvements
Amgen, AstraZeneca report CROSSING trial met co-primary and secondary endpoints
TIPRANKS  ·  08-27
Amgen, AstraZeneca report CROSSING trial met co-primary and secondary endpoints
AstraZeneca, Amgen Phase 3 Trial Shows Tezspire Eases Swallowing Difficulties for EoE Patients
MT Newswires Live  ·  08-27
AstraZeneca, Amgen Phase 3 Trial Shows Tezspire Eases Swallowing Difficulties for EoE Patients
Vertex Corp. Added to JPX-Nikkei Mid and Small Cap Index for FY2026
TIPRANKS  ·  08-27
Vertex Corp. Added to JPX-Nikkei Mid and Small Cap Index for FY2026
Vertex Corp. Refines Leadership Structure at Key Subsidiary Vertex Co.
TIPRANKS  ·  08-27
Vertex Corp. Refines Leadership Structure at Key Subsidiary Vertex Co.
AstraZeneca-Amgen Asthma Drug Succeeds in Late-Stage Oesophagus Disease Trial
Reuters  ·  08-27
AstraZeneca-Amgen Asthma Drug Succeeds in Late-Stage Oesophagus Disease Trial
Amgen - Tezspire Safety Profile Consistent with Approved Indications
THOMSON REUTERS  ·  08-27
Amgen - Tezspire Safety Profile Consistent with Approved Indications
Tezspire® Demonstrates Positive Phase 3 Results in Eosinophilic Esophagitis Across Both Co-Primary and All Key Secondary Endpoints
THOMSON REUTERS  ·  08-27
Tezspire® Demonstrates Positive Phase 3 Results in Eosinophilic Esophagitis Across Both Co-Primary and All Key Secondary Endpoints
Vertex to Present at Wells Fargo Healthcare Investor Conference Fireside Chat
Reuters  ·  08-27
Vertex to Present at Wells Fargo Healthcare Investor Conference Fireside Chat

Introduction

Company Name.
INVESCO BIOTECHNOLOGY & GENOME ETF
Affiliated Markets:
ARCA
Listing Date:
--
Main Business:
The fund generally will invest at least 90% of its total assets in securities that comprise the underlying index. The underlying index was composed of common stocks of U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.
Issue price:
--